Study: Chemotherapy to Treat Breast Cancer Increases Risk of Lung Cancer
Pharmacy Times
APRIL 19, 2024
Individuals treated with chemotherapy following a breast cancer diagnosis were more at risk of developing second primary lung cancer.
Chemotherapy Related Topics 
FDA Approves Nivolumab Plus Chemotherapy for Unresectable or Metastatic Urothelial Carcinoma
Drug Topics
MARCH 8, 2024
A clinical trial showed that nivolumab plus chemotherapy significantly improved overall survival and progression-free survival compared with a chemotherapy combination alone.
Chemotherapy 
98
98 Join 18,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
FDA Accepts sBLA for Dostarlimab With Chemotherapy to Treat Endometrial Cancer
Pharmacy Times
APRIL 25, 2024
Dostarlimab plus chemotherapy is the only immuno-oncology-based therapy that showed statistically significant and clinically meaningful survival benefit in the overall patient population.
Chemotherapy 65
65 
FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment
Pharmafile
MARCH 4, 2024
The drug has been approved in combination with chemotherapy (carboplatin-pemetrexed) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 […] The post FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment appeared (..)
Chemotherapy 110
110 
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
This new guidance will clearly impact the clinical research field, but how?
New chemotherapy treatment could benefit multiple cancer types
European Pharmaceutical Review
FEBRUARY 15, 2024
A clinical trial in malignant pleural mesothelioma (MPM) has demonstrated the first successful combination of chemotherapy with a drug targeting cancer’s metabolism developed for the asbestos-induced disease in two decades. The anti-cancer treatment combines the new drug ADI-PEG20 and traditional chemotherapy.
Chemotherapy 97
97 Chemotherapy 97
97 
FDA Approves Tislelizumab-jsgr for Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
Pharmacy Times
MARCH 14, 2024
Results from the phase 3 RATIONALE 302 trial showed tislelizumab-jsgr prolonged survival compared to chemotherapy in patients who received prior systemic treatment.
Chemotherapy 123
123 
Pembrolizumab plus chemotherapy improves overall survival compared to chemotherapy alone in advanced biliary tract cancer
Hospital Pharmacy Europe
APRIL 24, 2023
Using pembrolizumab plus gemcitabine and cisplatin improves overall survival compared to chemotherapy alone in advanced biliary tract cancer Patients with biliary tract cancers invariably present at a late stage when curative surgery is not possible. Adults were randomised 1:1 to pembrolizumab plus chemotherapy or placebo and chemotherapy.
Chemotherapy 98
98 
Atorvastatin shown to reduce cardiac dysfunction in anthracycline-based chemotherapy
Hospital Pharmacy Europe
AUGUST 10, 2023
The use of atorvastatin prior to anthracycline-based chemotherapy in lymphoma patients reduces the subsequent development of cardiac dysfunction, according to the findings of a randomised trial. The post Atorvastatin shown to reduce cardiac dysfunction in anthracycline-based chemotherapy appeared first on Hospital Pharmacy Europe.
Chemotherapy 97
97 
As Chemotherapy Drug Shortage Continues, Unimaginable Decisions and Lacking Accountability Reign
Pharmacy Times
JULY 24, 2023
Treatment providers have been forced to adapt and make potentially life-altering decisions for patients due to persistent chemotherapy drug shortages, all while solutions from the FDA and drug manufacturers remain scant.
Chemotherapy 123
123 
Pharmacist Follow-up Improves Patient Quality of Life After Emetogenic Chemotherapy
Drug Topics
NOVEMBER 8, 2022
Follow-ups from pharmacists show a significant increase in outpatient antiemetic drugs prescribed and quality of life in patients experiencing chemotherapy-induced nausea and vomiting.
Chemotherapy 144
144 Chemotherapy 144
144 
High BMI in Breast Cancer Patients Linked With Increased Cardiotoxicity During Chemotherapy
Drug Topics
AUGUST 9, 2023
A recent study being presented at the American College of Cardiology Latin America 2023 conference found the prevalence of cardiotoxicity among patients with breast cancer undergoing chemotherapy was 11.94%.
Chemotherapy 98
98 Chemotherapy 98
98 
Researchers Identify Chemotherapy Resistance Biomarkers in Triple-Negative Breast Cancer
Pharmacy Times
SEPTEMBER 2, 2022
DNA and RNA sequencing could provide insight about resistance to chemotherapy in patients suffering from triple-negative breast cancer.
Chemotherapy 156
156 Chemotherapy 156
156 
ASCO: Johnson & Johnson's Balversa tops chemotherapy in bladder cancer trial
Fierce Pharma
JUNE 5, 2023
Johnson & Johnson’s Balversa can keep some metastatic bladder cancer patients alive longer than chemotherapy, according to a study of 266 who have fibroblast growth factor receptor (FGFR) gene | Johnson & Johnson’s Balversa can keep some metastatic bladder cancer patients alive longer than chemotherapy, according to a study of 266 who have (..)
Chemotherapy 98
98 Chemotherapy 98
98 
Chemotherapy prescribing habits for stage 3 colon cancer changed following IDEA study
Hospital Pharmacy Europe
AUGUST 14, 2023
A significant and increasing trend towards the use of a three-month rather than six-month adjuvant chemotherapy regime in stage 3 colon cancer has been observed following publications from the IDEA collaboration abstract. In addition, CAPOX prescribing also significantly increased from 14% to 48% (p <0.001).
Chemotherapy 97
97 
STAT+: Hair loss is one of the most hated chemotherapy side effects. A new biotech hopes to prevent it
STAT
JANUARY 17, 2024
The chemotherapy Christine Ko was prescribed for her breast cancer is pretty much a guarantee for losing your hair. The company is currently developing an antibody that might reliably protect the head’s hair follicles from chemotherapy damage — if it works. But, to her, it wasn’t much of an option.
Chemotherapy 123
123 Chemotherapy 123
123 
Chemotherapy-Induced Diarrhea (CID) drugs in development, 2023
Pharmaceutical Technology
MARCH 20, 2024
GlobalData tracks 8 drugs in development for Chemotherapy-Induced Diarrhea (CID) by seven companies/universities/institutes. The top development phase for Chemotherapy-Induced Diarrhea (CID) is preclinical, with two drugs in that stage.
Chemotherapy 40
40 Chemotherapy 40
40 
Osimertinib With Chemotherapy Could Aid Overall Survival for NSCLC
Pharmacy Times
MARCH 27, 2024
Benefits throughout post-progression endpoints and outcomes were reported for osimertinib in combination with chemotherapy.
Chemotherapy 50
50 Chemotherapy 50
50 
Sustained-release chemotherapy has potential for bladder cancer
European Pharmaceutical Review
APRIL 7, 2023
A new, sustained-release chemotherapy delivery device inserted into the bladder, facilitated tumour response, a study has reported. The intravesical device, TAR-200, provides continuous, low-dose, local delivery of gemcitabine chemotherapy. All patients had transurethral resection of bladder tumour (TURBT) to remove visible tumour.
Chemotherapy 90
90 
Quizartinib Plus Chemotherapy Improved OS in Patients with AML, Little Hindrance to QOL
Pharmacy Times
DECEMBER 12, 2023
Compared to placebo plus chemotherapy, quizartinib plus chemotherapy improved OS without significant AEs and impact on QOL in patients with AML.
Chemotherapy 65
65 Chemotherapy 65
65 
‘The Top Line’: The chemotherapy drug shortage, plus this week’s headlines
Fierce Pharma
JULY 21, 2023
This week on "The Top Line," we discuss the chemotherapy drug shortage, plus Grail’s harassment lawsuit and the rest of this week’s headlines In this episode of "The Top Line," we talk with Vimala Raghavendran, the vice president of informatics and product development at U.S.
Chemotherapy 98
98 Chemotherapy 98
98 
Nivolumab Plus Chemotherapy Treatment Followed By Surgery Improved EFS in Patients With NSCLC
Pharmacy Times
OCTOBER 25, 2023
Compared to placebo plus chemotherapy, nivolumab plus chemotherapy had also improved event-free survival and both polymerase chain reaction and major pathologic response rates.
Chemotherapy 65
65 Chemotherapy 65
65 
STAT+: Merck, Daiichi Sankyo to partner on targeted chemotherapy drugs in deal worth up to $22 billion
STAT
OCTOBER 19, 2023
MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments. The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years.
Chemotherapy 127
127 Chemotherapy 127
127 
Amivantamab Plus Chemotherapy Reduced Risk of Disease Progression, Death in Patients With NSCLC
Pharmacy Times
OCTOBER 25, 2023
Compared to chemotherapy alone, amivantamab plus chemotherapy treatment with and without lazertinib had also demonstrated positive trends in OS and ORR in patients with NSCLC.
Chemotherapy 65
65 Chemotherapy 65
65 
'We can't forget about this': As chemotherapy shortage ebbs and flows, attention shifts to long-term solutions
Fierce Pharma
SEPTEMBER 27, 2023
It’s been about 10 months since FDA inspectors rebuked a | As some cancer centers struggle to secure access to key platinum-based chemotherapies, a national spotlight gives the issue newfound political importance. But will this be a turning point for the recurrent shortage issue? ASCO's Julie Gralow, M.D., certainly hopes so.
Chemotherapy 116
116 
Ocular Adverse Events Linked to Chemotherapies Paclitaxel and Docetaxel
Drug Topics
SEPTEMBER 6, 2022
Patients who received the chemotherapies paclitaxel and docetaxel were at an increased risk of adverse events of the eye.
Chemotherapy 98
98 Chemotherapy 98
98 
Amivantamab Plus Chemotherapy Reduced Risk of Disease Progression By 60% in Patients With NSCLC
Pharmacy Times
OCTOBER 24, 2023
Compared to chemotherapy alone, amivantamab plus chemotherapy had a better objective response rate and prolonged progression-free survival and overall survival.
Chemotherapy 65
65 Chemotherapy 65
65 
FDA Approves Tagrisso With Chemotherapy for EGFR-Mutated Advanced Lung Cancer
Pharmaceutical Commerce
FEBRUARY 19, 2024
Tagrisso (osimertinib) approved for use in combination with platinum-based chemotherapy in adults with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer harboring EGFR exon 19 deletions or exon 21 L858R mutations.
Chemotherapy 52
52 
FDA Approves Opdivo Plus Chemotherapy for Frontline Treatment of Unresectable, Metastatic Urothelial Carcinoma
PharmExec
MARCH 7, 2024
Opdivo (nivolumab) plus cisplatin and gemcitabine was found to improve overall survival and progression-free survival compared with chemotherapy alone in patients with unresectable or metastatic urothelial carcinoma.
Chemotherapy 52
52 
Study Reinforces Safety of Taxane-Based Chemotherapies for Pregnant Patients With Breast Cancer
Pharmacy Times
DECEMBER 8, 2023
In an interview at the 2023 San Antonio Breast Cancer Symposium, Ana Ferrigno Guajardo, MD, discussed research into the safety and efficacy of taxane-based chemotherapy use in pregnant patients with breast cancer.
Chemotherapy 65
65 Chemotherapy 65
65 
Durvalumab With Chemotherapy Shows Long-Term Overall Survival at 3 Years
Pharmacy Times
APRIL 18, 2024
The results were the longest survival follow-up ever reported for a phase 3 trial for biliary tract cancer.
Chemotherapy 145
145 Chemotherapy 145
145 
A gene test could guide decisions around chemotherapy for bowel cancer
Pharmafile
MARCH 3, 2023
Scientists from the Institute of Cancer Research London, Imperial College London and the Netherlands Cancer Institute have researched a gene test which can select which advanced bowel cancer patients will respond the best to chemotherapy. read more
Chemotherapy 83
83 
Phase 3 Results Show First-Line Amivantamab-vmjw Plus Chemotherapy Prolongs Survival In Patients With Advanced or Metastatic NSCLC
Pharmacy Times
JANUARY 11, 2024
A majority of patients who received first-line chemotherapy switched to amivantamab-vmjw plus chemotherapy as second-line therapy.
Chemotherapy 65
65 Chemotherapy 65
65 
FDA Approves Keytruda Plus Chemotherapy for Gastric, Gastroesophageal Junction Adenocarcinoma
PharmExec
NOVEMBER 17, 2023
Merck's pembrolizumab (Keytruda) plus fluoropyrimidine- and platinum-containing chemotherapy approved for the first-line treatment of patients with locally advanced unresectable or metastatic, HER2-negative GEJ adenocarcinoma.
Chemotherapy 52
52 
Neoadjuvant chemotherapy for colon cancer improves 2 year survival
Hospital Pharmacy Europe
FEBRUARY 14, 2023
The use of neoadjuvant chemotherapy has been shown to be of value at reducing tumour size and stage in patients with other operable cancers such as gastric and lower oesophageal adenocarcinomas. Neoadjuvant chemotherapy and cancer surgery outcomes A total of 686 patients assigned to NAC and 351 control patients were included in the analysis.
Chemotherapy 52
52 
Exercise Can Improve Chemotherapy-Induced Peripheral Neuropathy in Patients With Ovarian Cancer
Pharmacy Times
AUGUST 4, 2023
The affect of an aerobic exercise program was more prevalent in patients with ovarian cancer who had at least 1 symptom of chemotherapy-induced peripheral neuropathy at the beginning of the trial.
Chemotherapy 65
65 Chemotherapy 65
65 
FDA Approves New Chemotherapy-Free Treatment Option for Metastatic Colorectal Cancer
PharmExec
NOVEMBER 9, 2023
Fruquintinib (Fruzaqla) is the first novel chemotherapy-free treatment option approved for metastatic colorectal cancer in more than a decade.
Chemotherapy 59
59 
Determining Intensive Chemotherapy Eligibility in AML
Pharmacy Times
JUNE 21, 2022
Two medical professionals reveal what factors into intensive chemotherapy consideration and common toxicities found when undergoing treatment.
Chemotherapy 65
65 Chemotherapy 65
65 
FDA Approves Osimertinib With Chemotherapy for EGFRm NSCLC
Pharmacy Times
FEBRUARY 19, 2024
Osimertinib was previously approved as a monotherapy, the first-in-line global standard of care, for non–small cell lung cancer indications.
Chemotherapy 120
120 
Two-dose chemotherapy drug enters clinical trial for cancer patients
Pharmafile
NOVEMBER 28, 2022
South Korean biotech firm Hyundai Bioscience’s innovative chemotherapy drug may be able to complete cancer treatments in two doses. The new anticancer drug, Polytaxel, is set to enter a clinical trial on pancreatic cancer being held in Australia. read more.
Chemotherapy 78
78 Chemotherapy 78
78 
FDA Approves Merck's Keytruda With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma
Pharmaceutical Commerce
NOVEMBER 17, 2023
Pembrolizumab (Keytruda) plus fluoropyrimidine- and platinum-containing chemotherapy for locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction cancer approved by FDA after being found to lower the risk of metastasis or death.
Chemotherapy 52
52 
A study to avoid chemotherapy in patients with early HER-2+ breast cancer
pharmaphorum
FEBRUARY 10, 2021
The PHERGain II study’s goal is to find an effective therapeutic strategy that can reduce the use of chemotherapy and improve the quality of life of patients without compromising the clinical effectiveness of their treatment.
Chemotherapy 98
98 
Chemotherapy Induced Nausea and Vomiting drugs in development, 2023
Pharmaceutical Technology
DECEMBER 4, 2023
The Chemotherapy Induced Nausea and Vomiting drugs in development market research report provides comprehensive information on the therapeutics under development…
Chemotherapy 40
40 Chemotherapy 40
40 
Cytotoxic Chemotherapy May Reduce Gut Microbe Diversity, Contributing to Weight Gain in Patients With Breast Cancer
Pharmacy Times
JULY 17, 2023
Chemotherapy may increase inflammatory biomarkers that can impact the diversity of the gut microbiome, leading to serious anthropomorphic changes among women treated for early-stage breast cancer.
Chemotherapy 65
65 Chemotherapy 65
65 
Let's personalize your content